Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has remained a mystery lifelong debilitating disease for many years with little public profile, despite affecting 15-30 million people worldwide, and 20,000 in New Zealand. The lack of a molecular-based diagnostic test led to a strong belief the disease was an imagined somatic symptom disorder. In New Zealand, ME/CFS patients have been poorly served by health professionals and social agencies.
We have completed multiple molecular preclinical studies on affected patients and have established unequivocal evidence of a complex disturbance to their biochemistry, their DNA epigenetic code and overall physiology. Public recognition and awareness of ME/CFS has suddenly skyrocketed, with post SARS-CoV-2 patients exhibiting symptoms mimicking those of ME/CFS. The global incidence of ME/CFS may double as a result of this pandemic.
|Date||Tuesday, 25 May 2021|
|Time||12:00pm - 1:00pm|
|Event Category||Health Sciences|
|Location||Biochemistry Seminar Room G.13 (BIG13), Dunedin|
|Contact Name||Department of Biochemistry|